Development and Validation of a Multidimensional Prognostic Index for Mortality Based on a Standardized Multidimensional Assessment Schedule (MPI-SVaMA) in Community-Dwelling Older Subjects

Alberto Pilotto, Pietro Gallina, Andrea Fontana, Daniele Sancarlo, Salvatore Bazzano, Massimiliano Copetti, Stefania Maggi, Giulia Paroni, Francesco Marcato, Fabio Pellegrini, Daniele Donato, Luigi Ferrucci

Research output: Contribution to journalArticle

Abstract

Objectives: To develop and validate a Multidimensional Prognostic Index (MPI) for mortality based on information collected by the Multidimensional Assessment Schedule (SVaMA), the recommended standard tool for multidimensional assessment of community-dwelling older subjects in seven Italian regions. Design: Prospective cohort study. Participants: Community-dwelling subjects older than 65 years who underwent an SVaMA evaluation from 2004 to 2010 in Padova Health District, Veneto, Italy. Measurements: The MPI-SVaMA was calculated as a weighted (weights were derived from multivariate Cox regressions) linear combination of the following nine domains: age, sex, main diagnosis, and six scores, ie, the Short Portable Mental Status Questionnaire, the Barthel index (contains two domains: activities of daily living and mobility), the Exton-Smith scale, the Nursing Care Needs, and the Social Network Support by a structured interview. Subjects were followed for a median of 2 years; those who had not died were followed for at least 1 year. The MPI-SVaMA score ranged from 0 to 1 and 3 grades of severity of the MPI-SVaMA were calculated on the basis of estimated cutoffs. Discriminatory power and calibration were further assessed. Results: A total of 12,020 subjects (mean age 81.84 ± 7.97 years) were included. Two random cohorts were selected: (1) a development cohort, ie, 7876 subjects (mean age 81.79 ± 8.05, %females: 63.1) and (2) a validation cohort, ie, 4144 subjects (mean age: 81.95 ± 7.83, %females: 63.7).The discriminatory power for mortality of MPI-SVaMA was 0.828 (95% CI 0.817-0.838) and 0.832 (95% CI 0.818-0.845) at 1 month and 0.791 (95% CI 0.784-0.798) and 0.792 (95% CI 0.783-0.802) at 1 year in development and validation cohorts, respectively. MPI-SVaMA results were well calibrated showing lower than 10% differences between predicted and observed mortality, both in development and validation cohorts. Conclusions: The MPI-SVaMA is an accurate and well-calibrated prognostic tool for mortality in community-dwelling older subjects, and can be used in clinical decision making.

Original languageEnglish
Pages (from-to)287-292
Number of pages6
JournalJournal of the American Medical Directors Association
Volume14
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Independent Living
Appointments and Schedules
Mortality
Activities of Daily Living
Nursing Care
Social Support
Italy
Calibration
Linear Models
Cohort Studies
Prospective Studies
Interviews
Weights and Measures
Health

Keywords

  • Comprehensive geriatric assessment
  • Elderly
  • Mortality
  • Prognosis

ASJC Scopus subject areas

  • Medicine(all)
  • Nursing(all)
  • Health Policy

Cite this

Development and Validation of a Multidimensional Prognostic Index for Mortality Based on a Standardized Multidimensional Assessment Schedule (MPI-SVaMA) in Community-Dwelling Older Subjects. / Pilotto, Alberto; Gallina, Pietro; Fontana, Andrea; Sancarlo, Daniele; Bazzano, Salvatore; Copetti, Massimiliano; Maggi, Stefania; Paroni, Giulia; Marcato, Francesco; Pellegrini, Fabio; Donato, Daniele; Ferrucci, Luigi.

In: Journal of the American Medical Directors Association, Vol. 14, No. 4, 04.2013, p. 287-292.

Research output: Contribution to journalArticle

Pilotto, Alberto ; Gallina, Pietro ; Fontana, Andrea ; Sancarlo, Daniele ; Bazzano, Salvatore ; Copetti, Massimiliano ; Maggi, Stefania ; Paroni, Giulia ; Marcato, Francesco ; Pellegrini, Fabio ; Donato, Daniele ; Ferrucci, Luigi. / Development and Validation of a Multidimensional Prognostic Index for Mortality Based on a Standardized Multidimensional Assessment Schedule (MPI-SVaMA) in Community-Dwelling Older Subjects. In: Journal of the American Medical Directors Association. 2013 ; Vol. 14, No. 4. pp. 287-292.
@article{d438856aad354b09b9547feaaf1add62,
title = "Development and Validation of a Multidimensional Prognostic Index for Mortality Based on a Standardized Multidimensional Assessment Schedule (MPI-SVaMA) in Community-Dwelling Older Subjects",
abstract = "Objectives: To develop and validate a Multidimensional Prognostic Index (MPI) for mortality based on information collected by the Multidimensional Assessment Schedule (SVaMA), the recommended standard tool for multidimensional assessment of community-dwelling older subjects in seven Italian regions. Design: Prospective cohort study. Participants: Community-dwelling subjects older than 65 years who underwent an SVaMA evaluation from 2004 to 2010 in Padova Health District, Veneto, Italy. Measurements: The MPI-SVaMA was calculated as a weighted (weights were derived from multivariate Cox regressions) linear combination of the following nine domains: age, sex, main diagnosis, and six scores, ie, the Short Portable Mental Status Questionnaire, the Barthel index (contains two domains: activities of daily living and mobility), the Exton-Smith scale, the Nursing Care Needs, and the Social Network Support by a structured interview. Subjects were followed for a median of 2 years; those who had not died were followed for at least 1 year. The MPI-SVaMA score ranged from 0 to 1 and 3 grades of severity of the MPI-SVaMA were calculated on the basis of estimated cutoffs. Discriminatory power and calibration were further assessed. Results: A total of 12,020 subjects (mean age 81.84 ± 7.97 years) were included. Two random cohorts were selected: (1) a development cohort, ie, 7876 subjects (mean age 81.79 ± 8.05, {\%}females: 63.1) and (2) a validation cohort, ie, 4144 subjects (mean age: 81.95 ± 7.83, {\%}females: 63.7).The discriminatory power for mortality of MPI-SVaMA was 0.828 (95{\%} CI 0.817-0.838) and 0.832 (95{\%} CI 0.818-0.845) at 1 month and 0.791 (95{\%} CI 0.784-0.798) and 0.792 (95{\%} CI 0.783-0.802) at 1 year in development and validation cohorts, respectively. MPI-SVaMA results were well calibrated showing lower than 10{\%} differences between predicted and observed mortality, both in development and validation cohorts. Conclusions: The MPI-SVaMA is an accurate and well-calibrated prognostic tool for mortality in community-dwelling older subjects, and can be used in clinical decision making.",
keywords = "Comprehensive geriatric assessment, Elderly, Mortality, Prognosis",
author = "Alberto Pilotto and Pietro Gallina and Andrea Fontana and Daniele Sancarlo and Salvatore Bazzano and Massimiliano Copetti and Stefania Maggi and Giulia Paroni and Francesco Marcato and Fabio Pellegrini and Daniele Donato and Luigi Ferrucci",
year = "2013",
month = "4",
doi = "10.1016/j.jamda.2013.01.005",
language = "English",
volume = "14",
pages = "287--292",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Development and Validation of a Multidimensional Prognostic Index for Mortality Based on a Standardized Multidimensional Assessment Schedule (MPI-SVaMA) in Community-Dwelling Older Subjects

AU - Pilotto, Alberto

AU - Gallina, Pietro

AU - Fontana, Andrea

AU - Sancarlo, Daniele

AU - Bazzano, Salvatore

AU - Copetti, Massimiliano

AU - Maggi, Stefania

AU - Paroni, Giulia

AU - Marcato, Francesco

AU - Pellegrini, Fabio

AU - Donato, Daniele

AU - Ferrucci, Luigi

PY - 2013/4

Y1 - 2013/4

N2 - Objectives: To develop and validate a Multidimensional Prognostic Index (MPI) for mortality based on information collected by the Multidimensional Assessment Schedule (SVaMA), the recommended standard tool for multidimensional assessment of community-dwelling older subjects in seven Italian regions. Design: Prospective cohort study. Participants: Community-dwelling subjects older than 65 years who underwent an SVaMA evaluation from 2004 to 2010 in Padova Health District, Veneto, Italy. Measurements: The MPI-SVaMA was calculated as a weighted (weights were derived from multivariate Cox regressions) linear combination of the following nine domains: age, sex, main diagnosis, and six scores, ie, the Short Portable Mental Status Questionnaire, the Barthel index (contains two domains: activities of daily living and mobility), the Exton-Smith scale, the Nursing Care Needs, and the Social Network Support by a structured interview. Subjects were followed for a median of 2 years; those who had not died were followed for at least 1 year. The MPI-SVaMA score ranged from 0 to 1 and 3 grades of severity of the MPI-SVaMA were calculated on the basis of estimated cutoffs. Discriminatory power and calibration were further assessed. Results: A total of 12,020 subjects (mean age 81.84 ± 7.97 years) were included. Two random cohorts were selected: (1) a development cohort, ie, 7876 subjects (mean age 81.79 ± 8.05, %females: 63.1) and (2) a validation cohort, ie, 4144 subjects (mean age: 81.95 ± 7.83, %females: 63.7).The discriminatory power for mortality of MPI-SVaMA was 0.828 (95% CI 0.817-0.838) and 0.832 (95% CI 0.818-0.845) at 1 month and 0.791 (95% CI 0.784-0.798) and 0.792 (95% CI 0.783-0.802) at 1 year in development and validation cohorts, respectively. MPI-SVaMA results were well calibrated showing lower than 10% differences between predicted and observed mortality, both in development and validation cohorts. Conclusions: The MPI-SVaMA is an accurate and well-calibrated prognostic tool for mortality in community-dwelling older subjects, and can be used in clinical decision making.

AB - Objectives: To develop and validate a Multidimensional Prognostic Index (MPI) for mortality based on information collected by the Multidimensional Assessment Schedule (SVaMA), the recommended standard tool for multidimensional assessment of community-dwelling older subjects in seven Italian regions. Design: Prospective cohort study. Participants: Community-dwelling subjects older than 65 years who underwent an SVaMA evaluation from 2004 to 2010 in Padova Health District, Veneto, Italy. Measurements: The MPI-SVaMA was calculated as a weighted (weights were derived from multivariate Cox regressions) linear combination of the following nine domains: age, sex, main diagnosis, and six scores, ie, the Short Portable Mental Status Questionnaire, the Barthel index (contains two domains: activities of daily living and mobility), the Exton-Smith scale, the Nursing Care Needs, and the Social Network Support by a structured interview. Subjects were followed for a median of 2 years; those who had not died were followed for at least 1 year. The MPI-SVaMA score ranged from 0 to 1 and 3 grades of severity of the MPI-SVaMA were calculated on the basis of estimated cutoffs. Discriminatory power and calibration were further assessed. Results: A total of 12,020 subjects (mean age 81.84 ± 7.97 years) were included. Two random cohorts were selected: (1) a development cohort, ie, 7876 subjects (mean age 81.79 ± 8.05, %females: 63.1) and (2) a validation cohort, ie, 4144 subjects (mean age: 81.95 ± 7.83, %females: 63.7).The discriminatory power for mortality of MPI-SVaMA was 0.828 (95% CI 0.817-0.838) and 0.832 (95% CI 0.818-0.845) at 1 month and 0.791 (95% CI 0.784-0.798) and 0.792 (95% CI 0.783-0.802) at 1 year in development and validation cohorts, respectively. MPI-SVaMA results were well calibrated showing lower than 10% differences between predicted and observed mortality, both in development and validation cohorts. Conclusions: The MPI-SVaMA is an accurate and well-calibrated prognostic tool for mortality in community-dwelling older subjects, and can be used in clinical decision making.

KW - Comprehensive geriatric assessment

KW - Elderly

KW - Mortality

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84878015485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878015485&partnerID=8YFLogxK

U2 - 10.1016/j.jamda.2013.01.005

DO - 10.1016/j.jamda.2013.01.005

M3 - Article

C2 - 23402948

AN - SCOPUS:84878015485

VL - 14

SP - 287

EP - 292

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 4

ER -